Comparative Study of the Mutant Prevention Concentrations of Moxifloxacin, Levofloxacin, and Gemifloxacin against Pneumococci
| Autor: | Pamela McGhee, Kim L. Credito, Glenn A. Pankuch, Peter C. Appelbaum, Klaudia Kosowska-Shick |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Ofloxacin
medicine.drug_class Gemifloxacin Moxifloxacin Antibiotics Levofloxacin Microbial Sensitivity Tests Biology medicine.disease_cause Polymerase Chain Reaction Microbiology Drug Resistance Bacterial Streptococcus pneumoniae medicine Pharmacology (medical) Naphthyridines Mechanisms of Action: Physiological Effects Antibacterial agent Pharmacology Aza Compounds Streptococcaceae biology.organism_classification Anti-Bacterial Agents DNA Topoisomerases Type II Infectious Diseases Mutation Quinolines Fluoroquinolones medicine.drug |
| Zdroj: | Antimicrobial Agents and Chemotherapy. 54:673-677 |
| ISSN: | 1098-6596 0066-4804 |
| Popis: | We tested the propensity of three quinolones to select for resistant Streptococcus pneumoniae mutants by determining the mutant prevention concentration (MPC) against 100 clinical strains, some of which harbored mutations in type II topoisomerases. Compared with levofloxacin and gemifloxacin, moxifloxacin had the lowest number of strains with MPCs above the susceptibility breakpoint ( P < 0.001), thus representing a lower selective pressure for proliferation of resistant mutants. Only moxifloxacin gave a 50% MPC (MPC 50 ) value (1 μg/ml) within the susceptible range. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|